Interleukin-7 improves reconstitution of antiviral CD4 T cells  by Lu, H. et al.
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MULTIPLEXED GENOTYPING OF HUMAN MINOR HISTOCOMPATIBIL-
ITY ANTIGENS
Pietz, B.C.; DuChateau, B.K.; Warden, M.B.; Ellis, T.M. The Blood
Center of S.E. Wisconsin, Milwaukee, WI.
Minor histocompatibility antigens (mHA) induce T cell medi-
ated immune responses that have been associated with increased
risk of graft versus host disease and allograft rejection. Unlike HLA
genes, mHA are encoded by genetically and functionally unrelated
genes located throughout the chromosome. The role of mHA in
stem cell transplantation and the frequencies of mHA alleles in
large study populations remain unknown due in part to the lack of
a suitable high throughput method for mHA genotyping. Here we
describe the development and utility of a single tube, expandable,
multiplexed assay for genotyping mHA (HA-1, HA-2, HA-3,
HA-8, HB-1, CD31125, and CD31563) using the Luminex plat-
form. The assay utilizes a multiplexed allele-independent gated
ampliﬁcation of mHA genes followed by differential detection of
allele-speciﬁc primer products using the MultiCode system (Era-
gen Biosciences, Madison, WI). The alleles are interrogated using
a multiplex allele-speciﬁc primer extension reaction with primers
tagged with EraCodes, the products hybridized to Luminex beads,
and the hybridization duplex detected using streptavidin-PE. Us-
ing this assay, we generated an estimate of mHA allele frequencies
in a limited local donor population and are assessing the inﬂuence
of mHA disparities on outcomes of stem cell transplantation in a
large cohort of unrelated recipient-donor pairs.
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MOLECULAR CHARACTERIZATION OF HLA-A MISMATCHES FOR MOD-
ELING OUTCOMES ANALYSES
Baxter-Lowe, L.A.1; Maiers, M.2; Spellman, S.2; Fernandez-Vina,
M.3; Horowitz, M.4; Haagenson, M.2; Hurley, C.5 1. UCSF, San
Francisco, CA; 2. NMDP, Minneapolis, MN; 3. M.D. Anderson, Hous-
ton, TX; 4. Medical College of Wisconsin, Milwaukee, WI; 5. George-
town University, Washington, DC.
For allogeneic transplant candidates who have no HLA matched
donor, there are no well accepted guidelines for selecting an HLA
mismatched (MM) donor. To provide a foundation for developing
new models for ranking HLA MM donors, this investigation fo-
cuses on HLA-A MM because single HLA-A MM are observed in
a large proportion of patients. The molecular characteristics of 832
HLA-A MM were examined in 3,687 unrelated donor-recipient
pairs from NMDP facilitated transplants which had retrospective
high resolution HLA typing. There are a few high frequency MM
combinations that constitute a large proportion of the MM: 0201
vs 0205 (8%), 0201 vs 0206 (8%), 6801 vs 6802 (4%), 3001 vs 3002
(4%), and 0201 vs 6801 (4%). There are 12 MM combinations that
occur10 times and comprise 25% of the MM combinations. The
remaining MM combinations, which constitute 46% of the total,
are relatively infrequent and include 95 combinations that occur
only once in this population. Comparison of the protein sequences
of the peptide binding domain of mismatched HLAs revealed 1–28
amino acid differences. Of these, 17% were single amino acid
differences and 16% had 2–3 amino acid differences. Approxi-
mately 70% of MM amino acids were located in positions that alter
the environment of the bound peptide. For these residues, small
differences in the properties of the amino acid side chains can have
substantial effects on T cell allorecognition. Many HLA-A dispar-
ities (63%) were accompanied by additional HLA-A, -B, -C,
and/or -DRB1 MM. This emphasizes the need for models that
detect additive, synergistic, dominant and permissive effects. The
characteristics of HLA-A disparities suggest that traditional HLA
MM criteria that have been used for outcomes analyses may ob-
scure important molecular characteristics that underlie detrimental
or permissive HLA MM. The characteristics of the HLA-A MM
are likely to be unique and HLA locus-speciﬁc characteristics
should be carefully considered in future study designs. A multifac-
eted approach is proposed for studying the relationship between
HLA disparity and transplant outcomes that determines the risks
associated with (1) high/intermediate frequency disparities, (2)
categories of functionally similar HLA disparities, and (3) multiple
HLA MM with complex interactions. This multifaceted approach
is likely to provide clinically useful guidelines for selection of MM
donors and explain some of the controversies in the scientiﬁc
literature.
IMMUNE RECONSTITUTION
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IMPACT OF PLASMACYTOID DENDRITIC CELL RECOVERY ON OUT-
COME AFTER REDUCED-INTENSITY CONDITIONING ALLOGENEIC STEM
CELL TRANSPLANTATION
Mohty, M.; Blaise, D.; Faucher, C.; Bardou, V.J.; Gastaut, J.A.; Viens,
P.; Olive, D.; Gaugler, B. Institut Paoli-Calmettes, Marseille, France.
Among DC subsets, the reconstitution of the natural type I-in-
terferon-producing plasmacytoid DCs (PDC) has been proposed
to play a major role in establishing immune competence, given the
capacity of PDCs to efﬁciently expand either speciﬁc cytotoxic T
lymphocytes, or to promote regulatory T cells, contributing to an
impaired immune response. Therefore, we investigated the impact
of circulating PDCs measured at 3 months after RIC-allo-SCT, in
54 pts who received a RIC-allo-SCT from an HLA-identical sib-
ling, in order to determine whether this could provide a convenient
indicator for long term outcome. The median absolute count of
PDCs measured at 3 months was 0.725/L (range, 0–23.2). In a
multiple logistic regression analysis including relevant parameters,
only the absence of clinically signiﬁcant grade II-IV acute GVHD
was associated with an improved PDC recovery (P0.003;
OR6.4; 95% CI, 1.9–22). We also investigated whether PDCs
recovered after allo-SCT are functional in response to viral stim-
ulation. Pts experiencing grade 0-I aGVHD could secrete signiﬁ-
cantly higher amounts of IFN-alpha as compared to pts with grade
II-IV aGVHD (mean, 91 pg/ml vs. 0 pg/ml respectively; P0.002),
likely highlighting the deleterious impact of corticosteroids ther-
apy on PDC function. The CD34 stem cell dose and other
lymphoid subsets infused with the allograft did not affect PDC
recovery. Though PDC count could not predict death from pro-
gression or relapse, pts with a high PDC recovery proﬁle had an
improved overall survival (OS; P0.03), in contrast to pts with a
low PDC recovery proﬁle who had an increased incidence of late
transplant-related mortality (GVHD, infections) (P0.03). In ad-
dition, the overall incidence of late infections (viral, fungal and
bacterial) was signiﬁcantly higher in the low PDC recovery group
as compared to the high PDC recovery group (59% vs. 19%;
P0.002), illustrating the importance of PDCs in anti-infectious
immune responses. In a multivariate analysis, only a high PDC
count was signiﬁcantly predictive of a decreased risk of death
(P0.04; RR0.34; 95% CI, 0.12–0.96). The role and impact of
rare immune effector cells would tend to be more evident in truly
RIC and less toxic regimens. In this study, we could show that
monitoring of PDCs may be useful for pts management (closer
surveillance, infection prophylaxis), and may have a signiﬁcant
impact on the probability of a favorable outcome in the context of
RIC-allo-SCT.
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INTERLEUKIN-7 IMPROVES RECONSTITUTION OF ANTIVIRAL CD4 T
CELLS
Lu, H.; Zhao, Z.; Kalina, T.; Kiem, H.-P.; Storek, J. Fred Hutchinson
Cancer Research Center, Seattle, WA.
We evaluated whether long-term (2 months) administration of
interleukin-7 (IL7) hastens immune recovery in baboons rendered
severely lymphopenic by total body irradiation and anti-thymocyte
globulin. Four baboons were treated with recombinant baboon IL7
and three baboons with placebo. Median CD4 T cell count at the
end of IL7/placebo treatment was higher in the IL7-treated ani-
mals (2,262 vs 618/ml, p0.03). This appeared to be a result of
peripheral expansion rather than de novo generation. Median cy-
tomegalovirus-speciﬁc IFNg-producing CD4 T cell count at the
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end of IL7/placebo treatment was higher in the IL7-treated ani-
mals (122 vs 1/ml, p0.03). All animals were pretransplant cyto-
megalovirus seropositive. One animal died at the end of IL7 treat-
ment; necropsy showed extensive T cell inﬁltration of kidneys and
lungs. In conclusion, IL7 stimulates the expansion of CD4 T cells,
including functional anti-viral cells. Clinical risk:beneﬁt ratio
needs to be evaluated.
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DE NOVO GENERATION OF CD4 T CELLS AGAINST VIRUSES PRESENT
IN THE HOST DURING IMMUNE RECONSTITUTION
Kalina, T.; Lu, H.; Zhao, Z.; Kiem, H.-P.; Storek, J. Fred Hutchinson
Cancer Research Center and University of Washington, Seattle, WA.
Patients after hematopoietic cell transplantation lack naı¨ve T
cells because of insufﬁcient generation of T cells de novo (thymo-
poiesis). Ways to improve de novo generation have recently been
studied, using, e.g., prothymopoietic cytokines or a thymic or-
ganoid (“artiﬁcial thymus”). It is not known whether improved
thymopoiesis might result in more T cells only for pathogens that
are typically absent from the body (e.g., neopathogens like ebola
virus or cleared recall pathogens like measles virus) or also for
pathogens or malignant cells present in the body (e.g., herpesvi-
ruses that infected the host pretransplant or the leukemia that
necessitated hematopoietic cell transplantation). The latter T cells
may be more important, as posttransplant infections due to endog-
enous microorganisms (e.g., herpesviruses) and leukemic relapse
cause major morbidity and mortality. However, T cells recognizing
self-peptides should theoretically be deleted in the thymus by
negative selection. Peptides from the endogenous viruses or leu-
kemic cells might be considered by the thymus as self-peptides, and
T cells speciﬁc for these peptides might be deleted (negatively
selected). We demonstrated in four baboons infected with baboon
cytomegalovirus and baboon lymphocryptovirus (Epstein-Barr vi-
rus-like virus) that after autologous transplantation of yellow ﬂu-
orescent protein (YFP)-marked hematopoietic cells, YFP CD4 T
cells against these viruses were generated de novo. Thus the thymus
generates CD4 T cells against not only pathogens absent from the
host but also pathogens present in the host. This ﬁnding provides
a strong rationale to improve thymopoiesis in hematopoietic cell
transplant recipients.
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CROSS-REACTIVITY OF EPSTEIN BARR VIRUS-SPECIFIC CYTOTOXIC T
LYMPHOCYTES WITH A HLA-C LOCUS ALLELE
Keever-Taylor, C.A.; Ramadan, G.; Orental, R.J.; Davies, B.; Behn, B.;
Margolis, D.A. Medical College of Wisconsin, Milwaukee, WI.
The basis for T cell alloreactivity is thought to be primarily due
to cross-reactivity of antigen-speciﬁc T cells with Major Histo-
compatibility Complex alleles. The cross-reactivity of cytotoxic T
lymphocytes (CTL) from HLA-B8 individuals recognizing the
human herpesvirus IV (HHV4/EBV) FLRGRAYGL epitope en-
coded by the EBNA-3A latency antigen with self peptides pre-
sented on HLA-B4402, B35, and B14 are examples of this phe-
nomenon and may represent the mechanism by which herpes virus
infections augment graft vs host disease, allograft rejection and
autoimmunity. Here we describe an EBV-speciﬁc CTL line pre-
pared from a HLA-B8-negative haplo-identical parental hemato-
poietic progenitor cell donor to restore patient immunity to EBV,
that reacts strongly to non-EBV infected targets from the intended
recipient. The CTL line was primed 2 with donor-derived EBV-
transformed B lymphoblastoid cells lines (BLCL) at a responder:
stimulator ratio of 40:1 that was reduced to 4:1 at wk 3 with the
addition of IL-2 to the culture and was expanded to wk 5 at which
time it was tested for reactivity to donor BLCL and donor and
patient PHA blasts. The line showed potent reactivity to donor
BLCL (66.3% speciﬁc lysis at an effector:target ratio of 50:1), no
reactivity donor PHA blasts but unexpectedly, lysed patient PHA
blasts (41.6% at 50:1) in repeated assays. Screening of the line with
PHA blasts from individuals sharing one or two HLA alleles on the
mismatched patient haplotype revealed that lysis was directed to
HLA-C*0202. Screening of the EBV-CTL line with BLCL targets
from unrelated donors who shared donor HLA alleles but lacked
C*0202 showed that the line was partially HLA-restricted by
HLA-DQ-*0201, B*3701, B*0702, and C*0701. A new line from
the same donor primed for only two weeks with autologous BLCL
at a responder:stimulator ratio of 4:1 also showed strong reactivity
to donor BLCL and patient C*0202 PHA blasts. T cells produc-
ing IFN- in response to irradiated C*0202 PHA blasts were
selected from this line using a MACS column. Further character-
ization of the expanded MACS-selected CTL for EBV speciﬁc
antigen killing and HLA restriction is in progress. These data
further support cross-reactivity to peptide presented on self MHC
as the basis for T cell alloreactivity and illustrate the need for
careful screening of allo-EBV-CTL from HLA mismatched do-
nors with non-EBV infected patient targets to ensure that these
lines are safe to infuse into patients.
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CTL ACTIVITY OF IN VITRO-DERIVED MEMORY T CELLS IS MORE
EFFICIENT THAN NAI¨VE T CELLS IN SYNGENEIC RECIPIENTS IMMEDI-
ATELY FOLLOWING EXPERIMENTAL BMT
Roskos, M.; Levy, R.B. Department of Microbiology and Immunology,
University of Miami School of Medicine, Miami, FL.
We are interested in elucidating how transplanted memory CD8
T cells can contribute to the immune reconstitution of ablatively
conditioned BMT recipients. We have focused our studies on
memory CD8 T cells because they display more rapid, elevated
cytotoxicity compared to naı¨ve CD8 cells, and thus may make more
efﬁcient BMT adjuvants. A homogeneous TCR-transgenic (tg)
memory CD8 T population was generated in vitro and used in a
syngeneic murine BMT model to 1) investigate the homeostatic
proliferation and function of in vitro-derived memory T cells and
2) compare the CTL activity of these memory cells to that of naı¨ve
T cells in the reconstituting host. The in vitro-derived memory T
cell population (TM) was generated using either OT.I-RAG1/
or OT.I-GFP TCR tg mice. Brieﬂy, spleens from OT.I mice were
cultured for 3 days with rmIL-2 and OVA peptide, harvested, and
re-cultured for 2–4 days with rmIL-15. The resultant OT.I cells
expressed CD25lo, CD44hi, CD62L, and Ly6C, indicating a
central memory phenotype. The OT.I cells (1.5  106), together
with T cell-depleted B6 bone marrow (2  106), were transplanted
into 9.0 Gy-conditioned syngeneic recipients. Homeostatic prolif-
eration of TM was assessed by V5, GFP cell numbers in
recipient spleens 4 to 42 days post-BMT. TM expanded during the
ﬁrst 14 days (2 106/spleen) then maintained its number while the
spleen continued to increase for another two weeks. TM cell
number and phenotype remained unchanged90 days post-BMT.
CFSE-labeled OT.I-RAG1/ cells were used to precisely exam-
ine when, during the ﬁrst 2 weeks post-BMT, TM underwent
division. The ﬁrst several divisions were apparent as early as 3 days
post-BMT, and the TM population, as a whole, continued to
divide with 6 divisions observed by day 7. CTL function was
assessed within 14 days and then 28 days post-BMT using OVA-
pulsed targets. TM obtained from recipient spleens 7 days post-
BMT generated a more rapid, elevated CTL response compared to
transplanted naı¨ve OT.I cells (p 
 0.05). TM remained functional
at least 5 weeks post-BMT. In total, these ﬁndings demonstrate
that a homogeneous in vitro-derived memory CD8 T cell popula-
tion can efﬁciently expand and function immediately post-BMT.
Moreover, these memory CD8 T cells exhibit greater cytotoxic
activity compared to naı¨ve CD8 T cells, supporting the notion that
rapidly-generated, in vitro-derived memory CD8 T cells may have
the superior therapeutic potential immediately following BMT.
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RECONSTITUTION OF IMMUNITY TO ADENOVIRUS AFTER PEDIATRIC
BONE MARROW TRANSPLANT
Myers, G.D.; Leen, A.M.; Rooney, C.M.; Heslop, H.E.; Bollard, C.M.
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston,
TX; Department of Virology, Texas Childrens Hospital, Houston, TX;
The Methodist Hospital, Houston, TX.
Adenovirus has been shown to be a signiﬁcant cause of morbidity,
and mortality in the pediatric hematopoietic stem cell transplant
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